Please login to the form below

Not currently logged in
Email:
Password:

Versartis names chief financial officer

Joshua Brumm joins from Pharmacyclics

Versartis has named Joshua Brumm as its first chief financial officer.

Brumm joins from Pharmacyclics where he was principal financial officer and executive VP of finance.

He already has life sciences financial experience, having previously served as chief financial officer for Zeltiq Aesthetics and director of finance at Proteolix.

In his new role at Versartis, Brumm will lead the company's financial operations as it prepares to for the commercialisation of its phase III prospect VRS-317, which is in development as a treatment for growth hormone deficiency.

The company's CEO Dr Jeffrey Cleland said: "His appointment comes during a particularly exciting stage of development for Versartis and will significantly strengthen our management team."

18th December 2013

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics